 Thank you very much. Thank you for the opportunity. So actually, I made it finally. So I'm one of the neurologist and postdoctoral fellows from Melbourne. And this research was essentially generated from a long time ago in the lab, but also the clinical applications of it came about from my neurology training. And I remember one of the saddest clinics that I attended was the neuro-oncology or the brain tumor clinic. And going there as a neurology trainee, it was quite sad to see these patients. The majority of the patients were quite young. They had the rest of their life ahead of them. And most of the time, it was very unexpected, the diagnosis of brain tumor with implications for their life, for their livelihood, for their work, for their family, and the entire future for the individual. And I remember in terms of the actual consequences of that, it was quite drastic. And as clinicians, nothing has really changed. And even to this day, we continue to diagnose these diseases. We continue to prescribe the current standard treatment. But essentially, we are limited. And if you speak with any oncologist or any radiation oncologist or brain surgeon, they will tell you that we do what we can, but most of the time, we feel hopeless. And we feel at loss as to what we can do for these patients. So then this brings us to the laboratory component of this research. So while in the clinic, it can be quite hopeless and quite dramatic. In the lab, what we have been seeing is that if you take samples from these individuals that are having their tumor resected and you take it to the lab and you study it under the microscope and you actually culture it and look at these tumors over time, what you will see is that there's a pattern, that there's a hierarchy, there's order. So this ugly disease, it's got some elements that you can understand, that you can unravel. So from a scientist's perspective, you kind of get to have this innocence of hope that maybe we can understand these processes, maybe we can actually work through this and it will be hard, it will be difficult, but maybe there is hope in that. So our project is a link of the human or the patient side and then it brings about the laboratory aspect to it. So what we do is we look at tumors as the patient is having surgery with their consent, we take their tumor to the lab and examine that. And obviously hopefully the patient goes home but the tumor stays with us. So we look at the molecular profile of that tumor, we look at the genetic makeup of the tumor, we look at the cells that make up that tumor. And what we have found is that the immune cells, the microglia, these immune defense cells in the tumor, they are very critical for tumor proliferation or growth of that tumor. And we have also found that there's a specific receptor which is called a p2x7 receptor, it's basically a protein that sits in the membrane of these immune cells and we have found that this receptor is critical in the propagation of these tumors at least in the culture or in the petri dish. And if you inhibit this receptor by various agents, by various pharmacological agents, you can inhibit many processes, many steps in tumor proliferation. And that is quite, it gives us hope. And that was the research proposal that we have to the Brain Foundation and we are very grateful as a team of clinicians, as a team of scientists that the work is being recognized and we feel humbled and we acknowledge the contribution of the scientific committee. The patients also is a very important component of the research. Their family members, because they actually contribute quite a lot in a state of being, it's not the greatest moment of their life and in that setting they do contribute quite significantly. So we are grateful for that and we are also grateful for the opportunity. As helpless as this disease can be, I think as scientists, as clinicians we need to come together, collaboration and with work, it might be long hours, endless work, eventually, hopefully, there might be a change in the dynamics of human brain tumors or gliomas and hopefully with the aim of trying to develop therapies that are more effective than what we have available. So thank you for the opportunity, thank you to the Donors Brain Foundation and thank you for coming today.